Peninsula drugmaker's rollercoaster week ends with 62% stock drop

An FDA advisory committee by the thinnest of margins recommended that the agency approve the company's rare disease drug. Investors and regulators had questions.

Source: bizjournals.com Health Care:Physician Practices headlines - May 7, 2021 Category: American Health Authors: Ron Leuty Source Type: news